Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.
Journal: Hepatology communications
Published: September 17, 2020
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Journal: The lancet. Gastroenterology & hepatology
Published: May 21, 2017
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Journal: Contemporary clinical trials
Published: April 21, 2017
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: November 05, 2015
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
Journal: Hepatology (Baltimore, Md.)
Published: August 08, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 01, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Journal: Hepatology (Baltimore, Md.)
Published: December 10, 2014
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
Journal: Journal of hepatology
Published: August 06, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Journal: Lancet (London, England)
Published: August 01, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Journal: The New England journal of medicine
Published: April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Journal: The New England journal of medicine
Published: April 15, 2014
Last Updated: 09/26/2026